Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons

Abstract Background Janus kinase (JAK) inhibitors, such as baricitinib, are widely used to treat rheumatoid arthritis (RA). Clinical studies show that baricitinib is more effective at reducing pain than other similar drugs. Here, we aimed to elucidate the molecular mechanisms underlying the pain rel...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Kenta Makabe, Hiroyuki Okada, Naohiro Tachibana, Hisatoshi Ishikura, Norihito Ito, Masaru Tanaka, Ryota Chijimatsu, Asuka Terashima, Fumiko Yano, Meiko Asaka, Dai Yanagihara, Shuji Taketomi, Takumi Matsumoto, Sakae Tanaka, Yasunori Omata, Taku Saito
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-06-01
סדרה:	Arthritis Research & Therapy
נושאים:	Rheumatoid arthritis Pain-related behaviour CAIA model Baricitinib JAK/STAT3 pathway
גישה מקוונת:	https://doi.org/10.1186/s13075-024-03354-1
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!